Upjohn claims Wyeth Prempro promotions infringe Provera trademark in lawsuit.
Executive Summary
UPJOHN CHARGES WYETH WITH TRADEMARK INFRINGEMENT IN PREMPRO PROMOTION in a lawsuit filed April 17 in Kalamazoo, Mich. federal court. Upjohn is seeking an injunction against the marketing of Wyeth-Ayerst's Prempro combination of Premarin conjugated estrogens and Cycrin medroxyprogesterone acetate tablets, claiming that the product infringes Upjohn's trademark for the MPA brand Provera. Upjohn also alleges that Wyeth's promotions of the Premphase phased combination of Premarin and Cycrin violate the Provera trademark.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth